Many people label every brown patch on their face as “melasma.” In reality, the pigmentation left on skin varies widely — in origin, formation mechanism, and the depth at which it settles. Misidentification leads to mismanagement. Effective care requires a targeted approach by pigmentation type.
Not all brown marks are the same pigmentation
The brown marks that draw your attention in the mirror — are they melasma, a general blemish, or a post-inflammatory remnant? These are often grouped under the single label of “pigmentation.” But what’s frequently overlooked is this: while hyperpigmentation is one phenomenon, its causes and structures differ entirely by type. The common denominator across all forms of hyperpigmentation is melanin.
Melanin, which determines skin tone, is produced by cells called melanocytes located in the basal layer of the epidermis. Melanin is not inherently harmful. When UV rays threaten to damage the DNA of skin cells, melanocytes produce melanin to absorb and block that damage — this is how healthy skin is designed to respond. The problem arises when this response becomes excessive, or when the melanin produced distributes abnormally. At that point, melanin becomes visible on the skin surface as “hyperpigmentation.”
Same pigment, different causes:
Why each type requires its own target
The reason targeted care is necessary lies in the trigger that initiates melanin production — and that trigger differs by type. Whether it’s direct UV exposure, hormonal imbalance, or the residual mark left by acne or a procedure, all may appear as similarly colored brown marks on the surface. Yet their mechanisms and the depth at which they are distributed within the skin differ significantly. Some pigmentation stays in the superficial layers of the epidermis; other pigmentation is embedded deep in the dermis. This distinction is not merely academic — it is the standard that completely redirects the approach to treatment and management.
In some cases, the focus should be on inhibiting tyrosinase activity. In others, blocking the inflammatory pathway must come first. And in certain situations, preventing melanin transfer itself is the required approach. Treating all pigmentation as a single entity with one uniform method will inevitably yield limited results. Identifying where the brown mark on your skin originated is the first condition for effective pigmentation management.
Know the name to clear the mark
The most persistent pigmentation — always returning
Melasma
For anyone managing pigmentation concerns, melasma is the name that comes to mind first. It appears as brown to gray-brown patches that spread symmetrically across the center of the face — the cheeks, forehead, upper lip, and chin — with irregular and diffuse borders. Melasma management is complex because it does not arise from a single cause; it results from the interplay of UV exposure, the female hormones estrogen and progesterone, and genetic predisposition.
Classified by depth into epidermal, dermal, and mixed types, epidermal melasma appears brown and tends to respond more readily to treatment. Dermal melasma, which has a blue-gray tone, involves melanin embedded in deeper layers — making it more difficult to treat and more prone to recurrence. Mixed-type melasma, appearing gray-brown and most common in Asian skin, requires a long-term, multi-layered approach addressing both the epidermis and dermis. Single-session treatments alone are insufficient for both improvement and maintenance.
Recent research has indicated that increased vascularity and vascular endothelial growth factor (VEGF) activity in the dermis beneath melasma lesions may also play a role. This is why the experience of pigmentation resurfacing after a single episode of UV exposure or hormonal shift — even after diligent management — repeats itself. It is no exaggeration to say that maintaining results is the hardest part of melasma management.
Pigmentation that follows the seasons
Freckles
Unlike melasma, freckles appear as small, round brown spots scattered primarily across the nose and cheeks. They typically present as brown macules of around 1–5mm, with melanin confined to the basal layer of the epidermis. The fundamental difference between freckles and melasma lies in their mechanism. Where melasma involves excess melanin production triggered by hormones or compounding stimuli, freckles are closer to a constitutional, genetic condition — one in which the receptors responsible for producing melanin are inherently more sensitive to UV radiation.
Central to this is a polymorphism in the melanocortin-1 receptor (MC1R), which is commonly seen in individuals with blonde or red hair in Western populations. MC1R is a receptor that, when stimulated by external factors such as UV rays, promotes the production of eumelanin — the pigment responsible for brown to black tones. When a variant exists in this gene, the melanin response concentrates excessively in certain areas, forming freckles.
The seasonal pattern — darkening with greater sun exposure in summer and fading in winter — can be explained by this same mechanism. Freckles tend to first appear in childhood or adolescence and decrease in prevalence with age. They appear in clusters on UV-exposed areas such as the nose and cheeks, varying in intensity with sun exposure. Because freckles are confined to the superficial epidermis, they respond well to laser treatment. However, consistent sun protection and complementary esthetic therapies targeting freckles are strongly recommended for sustained management.
What inflammation leaves behind
Post-Inflammatory Hyperpigmentation (PIH)
The flat, brown to reddish-brown marks that appear after squeezing a blemish, following an allergic reaction, or after a minor wound heals — these are post-inflammatory hyperpigmentation. They are distinguished from scarring by the absence of textural disruption: the skin surface is flat, with no indentation or elevation. What makes this type distinct is that the trigger is the inflammatory response itself — not UV exposure or hormones.
To repair the damage caused by inflammation, capillaries dilate and blood, lymph fluid, and white blood cells migrate to the site of inflammation. This stimulates melanocytes, increasing melanin production. When basal layer damage accompanies this process, melanin drops into the dermis, where macrophages (melanophages) engulf it — causing pigmentation to persist in the skin for an extended period. What follows this stage requires particular attention.
With continued UV exposure afterward, the number of melanocytes increases sharply while the rate of keratinocyte turnover slows — causing the shedding of melanin-containing cells to stall, deepening the hyperpigmentation. Another common point of confusion is the distinction between post-inflammatory hyperpigmentation (PIH) and post-inflammatory erythema (PIE). PIE is a red discoloration caused by vascular dilation and may resolve as inflammation subsides — but hyperpigmentation can persist for months to years without appropriate management, even after inflammation has resolved.
PIH is particularly prevalent in individuals with medium to deep skin tones, and depending on the severity of inflammation and depth of pigmentation, natural fading can take anywhere from several months to several years. Ultimately, the most important principles in managing PIH are: resolving inflammation quickly, and avoiding all UV exposure during the recovery period.
The mark left by a hormonal surge
Chloasma (Mask of Pregnancy)
Aptly nicknamed the “mask of pregnancy,” chloasma presents as broad brown patches spanning the forehead, cheeks, upper lip, and nose. Though it closely resembles common melasma in appearance, its origin differs. During pregnancy, rapidly rising levels of estrogen and progesterone — combined with melanocyte-stimulating hormone (MSH) — act in concert to dramatically elevate melanin production. Because three hormones simultaneously stimulate melanocytes, even compared to typical melasma, the intensity and distribution range of chloasma is often more extensive.
After delivery, as hormones stabilize, pigmentation often fades naturally and may improve within several months — though in some cases it persists for years. Particularly if significant UV exposure occurred during pregnancy, melanin may have become embedded deep in the dermis, making it resistant to fading even postpartum. This makes sun protection during pregnancy more critical than at almost any other time. Even outside of pregnancy, similar pigmentation can develop in those taking oral contraceptives through a comparable mechanism — making this type worth considering when pigmentation appears after starting the pill.
The skin’s record of cumulative UV exposure
Age Spots
Age spots are flat, sharply defined brown to dark brown macules that appear on areas with chronic sun exposure — the backs of the hands, face, and shoulders. Larger and darker than freckles, they appear most commonly from around age 50 onward. As skin ages, its capacity to regulate pigment distribution declines and melanin accumulates in concentrated areas. These spots do not appear overnight — they are the result of decades of cumulative UV damage driving localized melanocyte proliferation.
Years of insufficient sun protection in earlier life are, in effect, recorded one by one on the skin in midlife and beyond. An important note: while age spots are benign, they must be distinguished from malignant conditions such as melanoma and basal cell carcinoma. If the border of a spot suddenly becomes irregular, its color changes, or itching or bleeding develops, a consultation with a dermatologist is strongly recommended.
Treatment Approaches by Pigmentation Type
Melasma
Reduce stimulation. Suppress melanin production at the source.
The first misconception to set aside in melasma management is that aggressive treatment equals better results. Melasma presents a paradox: heat and strong stimulation can trigger melanocyte overreaction, causing pigmentation to deepen. Mixed-type and dermal melasma in particular — where pigmentation has reached the dermis — can become more deeply embedded following high-intensity procedures. A calm, low-stimulation approach is therefore the foundational principle.
The treatment framework is structured to address the epidermis and dermis simultaneously. At the epidermal level, the priority is blocking melanin synthesis signals and inhibiting the transfer of already-produced melanin to keratinocytes. At the dermal level, regulating vascular response to reduce overall melanocyte activity is a complementary strategy. Low-heat LED therapy and clinical picosecond laser toning are among the appropriate options for melasma — each operating through distinct mechanisms.
LED therapy uses light energy at specific wavelengths to support cellular regeneration and inflammation regulation, assisting skin recovery without thermal stimulation. Picosecond laser delivers ultra-short pulses to physically shatter melanin particles, which are then cleared through the lymphatic system — making it a key modality in melasma treatment for its ability to target pigmentation directly while minimizing thermal damage.
In some cases, radiofrequency microneedling (RF) is used in conjunction. RF energy delivered directly to the dermis helps restore the basement membrane and suppresses the dermal vascular response that drives melanocyte hyperactivation — an approach that addresses the conditions allowing pigmentation to recur. In K-Beauty esthetic practice, iontophoresis and electroporation devices are also gaining attention as complementary tools for delivering actives such as niacinamide and tranexamic acid deep into the skin without physical stimulation.
Ultrasound-based devices are used not as a primary pigmentation treatment, but as a supportive modality — helping to restore the skin barrier and regulate inflammation, contributing to stable skin condition before and after treatment. Alongside all approaches, sun protection is a non-negotiable prerequisite for melasma management. Without it, every other intervention is compromised.
Freckles
Surface-level targeting: faster response, but consistent maintenance required
Because freckle pigmentation is confined to the basal layer of the epidermis, this type tends to respond more readily to treatment compared to others. Meaningful change can often be achieved by promoting epidermal cell turnover alone, without complex procedures targeting deeper layers. The core strategy is twofold.
First: consistently blocking the UV exposure that triggers melanin synthesis in daily life, suppressing pigment production at the source. Second: accelerating the epidermal cell renewal cycle to promote faster clearance of already-formed pigmentation. In a skincare routine, retinol can advance keratinocyte turnover, while alpha hydroxy acid (AHA) formulations help exfoliate surface pigmentation. Vitamin C targets already-formed melanin through its redox activity, while simultaneously providing antioxidant defense against further UV-induced damage.
If laser treatment is chosen, modalities capable of targeting the epidermal layer are appropriate. Without rigorous sun protection following treatment, stimulated melanocytes can reactivate, leading to recurrence. Response to treatment is relatively quick — but as long as the genetic predisposition remains, consistent suppression and maintenance is a more realistic goal than complete elimination.
Post-Inflammatory Hyperpigmentation (PIH)
Resolving inflammation quickly is the first step in pigmentation prevention
The most important principle in PIH management is preventing pigmentation from forming rather than eliminating it after the fact. Squeezing blemishes or otherwise irritating the skin amplifies the inflammatory response, leading to melanocyte hyperactivation. The moment inflammation occurs, how quickly it is calmed determines the depth and concentration of subsequent hyperpigmentation.
From a skin-depth perspective, PIH is classified as epidermal or dermal. When inflammation remains within the epidermis, pigmentation stays in the epidermal layer and can naturally clear through the skin cell renewal cycle. At this stage, a skincare approach using niacinamide — to address both anti-inflammatory activity and melanin transfer inhibition — combined with azelaic acid for tyrosinase suppression and soothing, is effective.
When inflammation penetrates the dermis, melanin becomes trapped within dermal macrophages and persists for considerably longer; promoting epidermal cell turnover alone has limited effect. In this case, retinoids to accelerate cell regeneration and vitamin C to reduce already-formed pigmentation through redox activity should be combined, alongside esthetic interventions designed to reach the dermal layer. This dual approach — simultaneously targeting inflammation and pigmentation suppression — is the structural core of PIH care. For dermal PIH, fractional laser therapy has gained traction for its ability to support skin regeneration, though it must be applied only after inflammation has fully resolved to avoid adverse outcomes.
Chloasma
A phased approach: strategy shifts by stage
The first thing to recognize in chloasma management is that approaches during pregnancy and after delivery must be entirely different. During pregnancy, ingredients that may affect the developing fetus and stimulating procedures are restricted — significantly narrowing the available scope of care. Retinol and retinoid formulations, as well as hydroquinone, are generally avoided, and high-concentration chemical peels or intensive procedures should be approached conservatively.
During pregnancy, the highest priority is rigorous UV protection to limit the signals stimulating melanin production, with gentle foundational skincare to maintain a stable skin barrier. Keeping the skin in a calm, stable state — rather than pursuing aggressive ingredient intervention or procedures — is the realistic goal for this period. Meaningful pigmentation care can begin after delivery, once hormones have stabilized.
After the hormonally driven melanocyte activity has subsided, care intensity can be gradually increased — introducing actives such as tranexamic acid, alpha-arbutin, and retinol in sequence. If pigmentation has become embedded in the dermis, epidermal skincare alone has limited reach. Consulting a dermatologist or licensed esthetician about dermal-targeting treatment protocols may be worth considering in those cases.
Age Spots
Beyond prevention: reactivating the skin’s renewal cycle is essential
Unlike other pigmentation types, age spots are the outcome of damage accumulated over a long period of time. At this stage, the focus shifts from prevention to managing existing pigmentation and minimizing the formation of new spots. As the skin ages, its cell renewal cycle slows and regenerative capacity declines — factors that accelerate pigment accumulation. Reactivating the skin’s regeneration cycle is therefore the central axis of management for this type.
Age spots are located in the epidermal layer, but when pigment density is high and the marks have been present for a long time, cell turnover alone produces slow results. Combining treatments that promote epidermal renewal with physical interventions including laser is therefore common practice. Corneotherapy — an approach targeting restoration of stratum corneum function — is also used in age spot management. By normalizing the function of the damaged stratum corneum, it improves the environment for pigment clearance itself. One point that must always be communicated: without consistent daily sun protection alongside physical treatments, new spots will continue to form around already-treated areas.
References
1. Melasma pathogenesi: a review of the latest research, pathological findings, and investigational therapies│Rajanala S, Maymone MBC, Vashi NA│Dermatol Online J│2019
2. Ephelides are more related to pigmentary constitutional host factors than solar lentigines.│Bastiaens MT, Westendorp RG, Vermeer BJ, Bavinck JN.│Pigment Cell Res│1999
3. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.│Sofen B, Prado G, Emer J│Skin Therapy Lett│2016
4. Chloasma–the mask of pregnancy│Bolanca I, Bolanca Z, Kuna K, Vuković A, Tuckar N, Herman R, Grubisić G│Coll Antropol│2008
Editor GAHEE, BAEK
Image Shutterstock
The Signature Magazine – May 2026 Issue